Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Apotex

PR Newswire December 7, 2016

Vanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences

PR Newswire November 14, 2016

Research Reports Coverage on Biotech Stocks -- Illumina, Peregrine Pharma, Lexicon Pharma, and Vanda Pharma

PR Newswire November 8, 2016

Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results

PR Newswire November 2, 2016

Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Taro

PR Newswire October 24, 2016

Vanda Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 2, 2016

PR Newswire October 12, 2016

Biotech Stocks Technical Reports -- Peregrine Pharma, PTC Therapeutics, Aratana Therapeutics, and Vanda Pharma

PR Newswire October 5, 2016

The Market In 5 Minutes: Indexes Looking To Close Week Higher

Benzinga.com  September 23, 2016

USPTO Dismisses Petition for Inter Partes Review of Fanapt® Patent

PR Newswire August 30, 2016

Vanda Patents Found Valid and Infringed in Fanapt® ANDA Litigation

PR Newswire August 25, 2016

Why Investors Love These Biotech's Stocks? - ImmunoGen, Immunomedics, Vanda Pharma, and Arrowhead Pharma

PR Newswire June 30, 2016

Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

PR Newswire June 20, 2016

A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus

Benzinga.com  June 15, 2016

Vanda Gets FDA Approval For Fanapt Marketing Exclusivity

Benzinga.com  June 15, 2016

FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia

PR Newswire June 15, 2016

Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference

PR Newswire June 3, 2016

Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults

PR Newswire May 26, 2016

Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results

PR Newswire May 4, 2016

Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016

PR Newswire April 14, 2016

Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions

Accesswire March 28, 2016